have a question, issue or just some feedback for us? we're here for you.

what can we help you with?

let us know how we can help

DISCLAIMER

The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.

compose your message

to*

from*

subject

message

message sent

email sent successfully

suggest a poll

you must have an account to suggest polls.

join now

rareLife solutions 606 Post Road East #397 Westport, CT 06880
You are receiving this because you have an account on www.oneMPSvoice.com
To unsubscribe from these emails, click here

Trusted Resources: News & Meetings

Latest announcements and gatherings

Clinical Trial and Research
Spotlight
Business
People
Happenings
Fundraising Events

Back to News & Meetings / Clinical Trial And Research

Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th Annual World Symposium™ 2022

REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient Investigational New Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).

RGX-111 is an investigational one-time gene therapy designed to deliver the gene that encodes the IDUA enzyme using the AAV9 vector. RGX-111 is administered directly to the CNS. The primary endpoint of the trial is to evaluate the safety of RGX-111. Secondary and exploratory endpoints include biomarkers of α-l-iduronidase (IDUA) enzyme activity in the cerebrospinal fluid (CSF), serum and urine, neurodevelopmental assessments, and caregiver reported outcomes.

Source: http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-presents-positive-initial-data-phase-iii-trial-rgx-111

Discuss in Social Wall

Share to rareTeam

Bookmark

send a message

send to:
subject:
message:

edit tags:

Reset password

Mobile

Enter Phone Number

Enter the code

Almost done!

We just send a four digit code to your mobile number. Enter it here to login!

Didn't receive the code? Re-send
Or login in with your password instead

password changed successfully!

please log in with your email address and new password.

your activation key expired

this confirmation key has expired. please try to log in again or resend confirmation email.

confirmation email sent

a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.

password reset email sent

an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.

If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.

your account is now activated!

Join the community

This feature is only available to members.

Already have an account? Log in.

I have read and understand the oneMPSvoice privacy policy and terms of use.

Almost done!

We just sent a four digit code to your mobile number. Enter it here to log in!

Please Wait!!!

Didn't receive the code? Re-send
Or log in in with your password instead

Log in

This feature is only available to members.

Don't have an account? Click here to register.

you haven't confirmed your email address yet. resend confirmation email

Forget your password? Reset here.

or register with

Need to get in touch?

Trusted Resources Home

Education

People & Places

News & Meetings

Videos & Visuals

Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th Annual World Symposium™ 2022

Related Content

Powered by

Trusted Resources Home

Education

People & Places

Community Center

News & Meetings

Videos & Visuals

Trusted Resources: News & Meetings

Latest announcements and gatherings

Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th Annual World Symposium™ 2022

Related Content

Powered by